Traders should prepare for potential volatility following the March 5 earnings release. Monitor the upcoming financial results for revenue, cash runway, and R&D spend, which will be critical for assessing the company's development trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $3.17entry
- T+1 · 9mo ago −1.58%α −0.66% · $3.12
- T+5 · 8mo ago −2.84%α −1.63% · $3.08
- T+20 · 8mo ago +18.93%α +26.87% · $3.77
- T+60 · 6mo ago +29.65%α +20.33% · $4.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced it will release its full-year 2025 financial results and provide a business update on March 5, 2026, followed by a conference call. The press release contains no financial data or material operational updates, only logistical details for the upcoming earnings event.
Key Facts
- Evaxion will report full-year 2025 financial results on March 5, 2026, before Nasdaq opens.
- Management will host a conference call and webcast the same day at 08:30 EST / 14:30 CET.
- No financial results, guidance, or material business updates were disclosed in this announcement.
- The release includes forward-looking statements and risk disclosures typical of public biotech companies.
Financial Impact
No financial impact from this announcement alone, no data disclosed.
Risk Factors
- Low liquidity and high volatility risk due to small market cap ($26M).
- Forward-looking statements suggest significant risks around funding, clinical development, and regulatory pathways.
- No financials or updates provided, actual results could surprise to the upside or downside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247291 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers